Cited by 1,031Chemotherapy-induced cardiotoxicity and mitigationCardiac tumors and thrombiHIV-related health complications and treatments

The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Open access

Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A.R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M.G., Orecchia, R., de Azambuja, E., Zamorano, J.L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C.M., Dent, S., Jordan, K.·2020·Annals of Oncology

DOI 10.1016/j.annonc.2019.10.023PMC PMC8019325

Open this paper in CoChat — free account Open PDF

Abstract

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2019.10.023

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945

Show all 221 references

Sorted by citations

Items 501–600 of 999

Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events
Losurdo, A., Panico, C., Catalano, C., Serio, S., Giordano, L., Monti, L., Catapano, F., Figliozzi, S., D’Andrea, C., Dipasquale, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010568 · Cited by 5
Cardiovascular disease in breast cancer patients: a nationwide real-world evidence study 2013–20
Engebretsen, I., Oteiza, F., Birkelund, E. F., Brandal, S. M., Bugge, C., & Halvorsen, S. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf043 · Cited by 5
An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study
Yoodee, J., Sookprasert, A., Sanguanboonyaphong, P., Chanthawong, S., Seateaw, M., & Subongkot, S. (2021) · Clinics and Practice · doi:10.3390/clinpract11030064 · Cited by 5
The Agreement of a Two- and a Three-Dimensional Speckle-Tracking Global Longitudinal Strain
Plášek, J., Rychlý, T., Drieniková, D., Cisovský, O., Grézl, T., Homza, M., & Václavík, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092402 · Cited by 5
Role of Myocardial Strain Imaging in Cancer Therapy–Related Cardiac Dysfunction
Chaganti, B. T., Negishi, K., & Okajima, K. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01692-7 · Cited by 5
Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada
Rushton, M. K., Kappel, C., Lima, I. S. F., Tuna, M., Pritchard, K. I., Hawken, S., & Dent, S. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.850674 · Cited by 5
Self-citation
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy
Zduniak, A., Lévêque, É., Perdrix, A., Etancelin, P., Ménard, A., Lenain, P., Contentin, N., Pépin, L., Leprêtre, S., Lemasle, É., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2123222 · Cited by 5
Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience
Lisi, D. D., Madaudo, C., Fazio, L. D., Gulotta, A., Triolo, O. F., Galassi, A. R., Incorvaia, L., Russo, A. D., & Novo, G. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10010023 · Cited by 5
Prevalence of cancer therapy cardiotoxicity as assessed by imaging procedures: A scoping review
Cantoni, V., Green, R., Assante, R., D’Antonio, A., Maio, F., Criscuolo, E., Bologna, R., Petretta, M., Cuocolo, A., & Acampa, W. (2023) · Cancer Medicine · doi:10.1002/cam4.5854 · Cited by 5
Stratifying breast cancer patients by baseline risk of cardiotoxic complications linked to chemotherapy
Tlegenova, Z. S., Balmagambetova, S. K., Zholdin, B., Kurmanalina, G. L., Talipova, I., Koyshybaev, A. K., Nurmanova, D., Sultanbekova, G., Baspayeva, M., Madinova, S., et al. (2023) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/13325 · Cited by 5
Lethal Immune Myocarditis and Myasthenia Gravis Due to Anti-PD-1 Treatment for a Bladder Cancer Patient: A Case Report and Possible Treatment Inspiration
Gao, P., Li, X., He, Z., Zhang, H., Zhang, Z., & Liu, Z. (2024) · International Medical Case Reports Journal · doi:10.2147/imcrj.s449525 · Cited by 5
Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China
Wang, G., Qin, J., Nong, W., Ma, D., Wang, C., Yu, H., Tang, S., Chen, M., Gao, J., Gao, T., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105763 · Cited by 5
Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
Geuna, E., Lombardi, P., Martinello, R., Garino, D., Bonzano, A., Galizia, D., Nuzzo, A., Berchialla, P., Becco, P., Mangioni, M., et al. (2020) · Cancers · doi:10.3390/cancers12020327 · Cited by 5
Patient reported physical and mental health changes associated with a comprehensive cardiovascular risk reduction program for women with breast cancer receiving potentially cardiotoxic chemotherapy
Fradley, M. G., Alomar, M., Kilpatrick, M. W., Shields, B., Tran, N., Best, A., Bianco, E., Armanious, M. A., Vautier, R. A., Kip, K. E., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00107-w · Cited by 5
Self-citation
Cardio-Oncology Educational Program: National Survey as the First Step to Start
Kozhukhov, S., & Dovganych, N. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.697240 · Cited by 5
Cardio-oncology: Implications for Clinical Practice for Women
Kassaian, S. E., Gandhi, B., & Barac, A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01779-1 · Cited by 5
Self-citation
The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy
Szponar, J., Ciechański, E., Ostrowska-Leśko, M., Gorska, A. A., Tchórz, M., Dąbrowska, A. M., Dudka, J., Murias, M., Kowalczyk, M., Korga-Plewko, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210202 · Cited by 5
Health status and mental distress in people with cancer and comorbid conditions: The Australian National Health Survey analysis
Ng, H. S., Woodman, R. J., & Koczwara, B. (2023) · Cancer Medicine · doi:10.1002/cam4.6291 · Cited by 4
Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology
Kersting, D., Settelmeier, S., Mavroeidi, I. A., Herrmann, K., Seifert, R., & Rischpler, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073802 · Cited by 5
The Potential Impact of the 2022 ESC Cardio-Oncology Guidelines on Clinical Practice in China
Tse, G., Shao, Q., Liu, J., & Zhang, Y. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.01.003 · Cited by 6
Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer
Le, J. N., Gasho, J. O., Peony, O., Singh, A., Silos, K. D., Kim, S., Nguyen, A. T., Kamrava, M. R., Mirhadi, A. J., Hakimian, B., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1485033 · Cited by 4
Development and validation of a transformer-based deep learning model for predicting distant metastasis in non-small cell lung cancer using 18FDG PET/CT images
Hu, N., Luo, Y., Tang, M., Yan, G., Yuan, S., Li, F., & Lei, P. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04014-9 · Cited by 4
Cardiac Surgery and Postoperative Atrial Fibrillation: The Role of Cancer
Georghiou, G. P., Georghiou, P., Georgiou, A., & Triposkiadis, F. K. (2025) · Medicina · doi:10.3390/medicina61101815 · Cited by 4
Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors’ needs
Gallego, A., Beato, C., Brozos, E., de la Cruz, S., & García, R. V. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03571-9 · Cited by 5
Left ventricular trabecular complexity for risk stratification of cancer therapy–related cardiac dysfunction in breast cancer
Shen, H., Xu, Q. Y., Tu, C., Peng, Y., Xie, Y., Miao, Z., Yang, R., & Zhang, J. (2025) · MedComm · doi:10.1002/mco2.70004 · Cited by 4
Is dyslipidemia a risk factor for trastuzumab-induced cardiotoxicity in breast cancer patients? A systematic review and meta-analysis
Pinho, J., Carvalho, M. M., Paiva, M. S., Tavares, N., Santos, C., & Sousa, C. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.10.016 · Cited by 4
Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma
Nakayama, T., Oshima, Y., Shintani, Y., Yamamoto, J., Yokoi, M., Ito, T., Wakami, K., Kitada, S., Goto, T., Hashimoto, H., et al. (2022) · Circulation Reports · doi:10.1253/circrep.cr-21-0145 · Cited by 4
Myocardial Dysfunction in Patients with Cancer
Koutroumpakis, E., Agrawal, N., Palaskas, N. L., Abe, J., Iliescu, C., Yusuf, S. W., & Deswal, A. M. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.011 · Cited by 6
The Association Between Medication Use in Older Women with Early-Stage Operable Primary Breast Cancer and Decision Regarding Primary Treatment
Tse, N., Parks, R. M., Holmes, H. M., & Cheung, K. (2023) · The Oncologist · doi:10.1093/oncolo/oyac278 · Cited by 4
Risk and Management of Patients with Cancer and Heart Disease
Hill, L., Delgado, B., Lambrinou, E., Mannion, T., Harbinson, M., & McCune, C. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00305-w · Cited by 5
Late-onset doxorubicin-induced congestive heart failure in an elderly cancer survivor: A case report
Suto, H., Suto, M., Inui, Y., & Okamura, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1124276 · Cited by 4
Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system
Al‐Jazairi, A. S., Bahammam, N., Aljuaid, D., Almutairi, L., Alshahrani, S., Albuhairan, N., Cahusac, P., & Korayem, G. B. (2023) · Cardio-Oncology · doi:10.1186/s40959-023-00184-z · Cited by 4
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Alizadehasl, A., Mohseni, M., Roudini, K., & Firoozbakhsh, P. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00220-6 · Cited by 4
Long-term cardiovascular risk reduction after gastric cancer surgery: a nationwide cohort study
Kwon, Y., Kim, D., Kim, S., Ha, J., Hwang, J., Park, S. S., & Kwon, J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001404 · Cited by 4
New insight in cervical cancer diagnosis using convolution neural network architecture
Khozaimi, A., & Mahmudy, W. F. (2024) · IAES International Journal of Artificial Intelligence · doi:10.11591/ijai.v13.i3.pp3092-3100 · Cited by 4
Diretriz Brasileira sobre a Saúde Cardiovascular no Climatério e na Menopausa – 2024
de Oliveira, G. M. M., de Almeida, M. C. C., Artucio, C., Espíndola, L. N., Rivera, M. A. M., Filho, A. L. D. S., Marques-Santos, C., Fernandes, C. E., Albuquerque, C. J. D. M., Freire, C. M. V., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240478 · Cited by 24
Cancer and Heart Failure: Dangerous Liaisons
Bertolini, D., Pizzi, C., Donal, E., & Galli, E. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11090263 · Cited by 4
A randomized controlled trial of gamification to increase physical activity among black and Hispanic breast and prostate cancer survivors: Rationale and design of the ALLSTAR clinical trial
Fanaroff, A. C., Orr, J. A., Anucha, C., Kim, E., Rareshide, C. A. L., Echevarria, M., Rodarte, S., Kassabian, M., Balasian, E., Ky, B., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.10.021 · Cited by 5
Self-citation
Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50%
Murg, S. I., Matiș, L., Moldovan, A. F., Popovici, D. I., Negru, A. G., Ghitea, T. C., & Popescu, M. I. (2025) · Medicina · doi:10.3390/medicina61020301 · Cited by 4
Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence
Ogunniyi, K. E., Djunadi, T. A., Adewara, O., Babawale, I., Akinmoju, O. D., Olaiya, V. O., Nwatamole, B. C., Shazad, S., Patel, D., Popoola, H. A., et al. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10038-y · Cited by 6
Cell Therapy Improves Cardiac Function in Anthracycline-Induced Cardiomyopathy Preclinical Models: A Systematic Review and Meta-Analysis
Lopes, G. M., Grudzinski, P. B., Nardi, N. B., & Leguisamo, N. M. (2020) · Stem Cells and Development · doi:10.1089/scd.2020.0044 · Cited by 4
Diagnostic aspects of cardiovascular complications following chemotherapy
Fashafsha, Z. Z. A., Фератовна, М. Д., Kopylov, F. Y., Salpagarova, Z. K., & Aa, B. (2022) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio20221501140 · Cited by 4
CARDIOTOXICITY OF CYCLOPHOSPHAMIDE: CURRENT STATE OF THE PROBLEM
Арманович, А. А., & Kaktursky, L. V. (2022) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2022.03.14 · Cited by 4
Multimodality Imaging for Cardiotoxicity: State of the Art and Future Perspectives
Artico, J., Abiodun, A., Shiwani, H., Kurdi, H., Chen, D. H., Tyebally, S. M., Moon, J., Westwood, M. A., & Manisty, C. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001281 · Cited by 4
Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists
Liu, B., Wang, Y., Lyu, D., & Ma, F. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002133 · Cited by 4
Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies
Scott, S. S., Greenlee, A. N., Schwendeman, E. J., Mohammad, S. J., Naughton, M. T., Matzko, A., Diallo, M., Stein, M., Revan, R., Zaramo, T. Z., et al. (2022) · Springer eBooks · doi:10.1007/978-3-031-08309-9_4 · Cited by 4
Preventive strategies of cancer therapeutics-related cardiotoxicity in childhood cancer survivors: a protocol of systematic review
Zhang, X., Wang, Q., Yang, K.-L., Wei, D., & Liu, X. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-065776 · Cited by 4
Left ventricular function and coronary microcirculation in patients with mild reduced ejection fraction after STEMI
Ma, Y., Wang, L., Jin, W., Zhu, T., Liu, J., Zhao, H., Wang, J., Lu, M., Cheng-fu, C. A. O., & Jiang, B. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02846-9 · Cited by 5
Early echocardiographic alterations in cancer patients during chemotherapy
Fashafsha, Z. Z. A., Chomakhidze, P. S., Фератовна, М. Д., Suvorov, А. Y., Sekacheva, M. I., Poddubskaya, E. V., Tyukanova, E. S., Sankova, M. V., Ozova, M. A., Levina, V. D., et al. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5093 · Cited by 4
Association between radiotherapy and risk of death from cardiovascular diseases in lung and bronchus cancer
Zhong, Y., Zhang, Y., Wang, Y., Gao, Y., Wang, Y., Li, X., Ru, S., Guo, N., Qiu, J., & Zhang, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1068957 · Cited by 4
Association between Cardiovascular Response and Inflammatory Cytokines in Non-Small Cell Lung Cancer Patients
Wang, X., Cao, M., Liu, Z., Chen, L., Zhou, Y., Gao, P., & Zou, Y. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10040173 · Cited by 4
Efficacy of exercise training for improving vascular dysfunction in people with cancer: a systematic review with meta-analyses
Vear, N. K., Moon, Y., Mielke, G. I., Skinner, T. L., Coombes, J. S., McCarthy, A. L., Abbott, C. R., & Bailey, T. G. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01372-7 · Cited by 4
Methods for assessing comorbidity and its role in patients with cardiac pathology
Blokhin, A., Shishkin, A. N., & Рафаилович, М. С. (2023) · Vestnik of Saint Petersburg University Medicine · doi:10.21638/spbu11.2023.201 · Cited by 4
New Concepts in Cardio-Oncology
Zagami, P., Nicolò, E., Corti, C., Valenza, C., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_12 · Cited by 4
Self-citation
Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC
Chen, L., Zhang, S. X., Gong, L., & Zhang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1404045 · Cited by 4
Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients
Cronin, M., Lowery, A., McInerney, V., Wijns, W. C., Kerin, M. J., Keane, M., Blazkova, S., Neiuroukh, D., Martin, M., & Soliman, O. I. I. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07322-w · Cited by 4
Increased risk of cardiovascular disease among kidney cancer survivors: a nationwide population-based cohort study
Jung, M., Choo, E., Li, S., Deng, Z., Li, J., Li, M., Basran, S. S., Lee, S., Langston, M. E., & Chung, B. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1420333 · Cited by 4
Cardiometabolic risk in childhood cancer survivors
LUONGO, C., RANDAZZO, E., IUGHETTI, L., IORGI, N. D., LOCHE, S., Maghnie, M., VALERIO, G., & Delvecchio, M. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06544-7 · Cited by 4
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up
Pokorná, Z., Kollárová-Brázdová, P., Lenčová-Popelová, O., Jirkovský, E., Kubeš, J., Mazurová, Y., Adamcová, M., Holečková, M., Palička, V., Šimůnek, T., et al. (2021) · Clinical Science · doi:10.1042/cs20210836 · Cited by 4
Atrial Fibrillation in Cancer Patients: Who is at Risk?
Vasyuk, Y. A., Shupenina, E. Y., Vyzhigin, D. A., Novosel, E. O., & Gallinger, K. V. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-12-03 · Cited by 4
Case report: challenges in monitoring and treatment of anthracycline induced cardiotoxicity in young adults with osteosarcoma
Heemelaar, J. C., Janson, J. A., Braun, J., Speetjens, F. M., van de Sande, M. A. J., Hugo, J. D. V., Barge‐Schaapveld, D. Q. C. M., Beeres, S. L. M. A., Tops, L. F., Gelderblom, H. A. J., et al. (2022) · Cardio-Oncology · doi:10.1186/s40959-022-00145-y · Cited by 4
Advancing the care of individuals with cancer through innovation & technology: Proceedings from the cardiology oncology innovation summit 2020 and 2021
Brown, S.-A. N., Beavers, C. J., Bauer, B. S., Cheng, R. K.-H., Berman, G., Marshall, C. H., Guha, A., Jain, P., Steward, A., DeCara, J. M., et al. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100354 · Cited by 4
Self-citation
Comparative capabilities of the speckle-tracking echocardiography technologiesin two-dimensional and three-dimensional modes in the detection of subclinical cardiotoxicity in patients with breast cancer
Saidova, M. A., Avalyan, A. A., Ощепкова, Е. В., Шитов, В. Н., & Chazova, I. E. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.12.200431 · Cited by 4
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens
Johnson, K. C., Quiroga, D. M., Sudheendra, P. K., & Wesolowski, R. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2063844 · Cited by 4
Cardiotoxicity in Oncology Guidelines: Discrepancies Do Matter
Tan, S., Kader, Z., Day, D., Chen, D. H., Nicholls, S. J., & Ramkumar, S. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.02.007 · Cited by 4
Impact of Aerobic Training on Cardiovascular Function, Fitness, and Patient Reported Outcomes During Anthracycline Chemotherapy: A Case Series in Women With Breast Cancer
Murray, J., Bennett, H., Selva‐Nayagam, S., Joshi, R., Bezak, E., & Perry, R. (2023) · Integrative Cancer Therapies · doi:10.1177/15347354231210874 · Cited by 3
Sex-specific risk of heart failure and acute myocardial infarction associated with osimertinib in older patients with non-small cell lung cancer
Byun, J., Han, S., Liu, Y., & Park, C. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241264721 · Cited by 3
Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies
Chen, C., Zheng, H., Wang, Y., Tong, Y., Zhang, H., Xie, S., Ma, X., Jiang, M., Gong, Z., Yan, T., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1477679 · Cited by 3
Interdisciplinary Management of Cardiotoxicity in Outpatient Settings: A Survey on Practices, Perceptions and Potential for Improvement
Quick, S., Payo-Anez, L., de Almeida, C. M. C., Schmitt, J. M., Ibrahim, K. S. M. H., Koesters, M., Christoph, M., Haase, T., & Harst, L. (2025) · European Cardiology Review · doi:10.15420/ecr.2023.49 · Cited by 3
TPNET: A Time-Sensitive Small Sample Multimodal Network for Cardiotoxicity Risk Prediction
He, Y., Zhang, F., Hu, K., Sun, C., Geng, J., Ren, N., & Su, R. (2025) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3552819 · Cited by 3
Advances in Targeted Autophagy Modulation Strategies to Treat Cancer and Associated Treatment-Induced Cardiotoxicity
Ling, L. A., Boukhalfa, A., Kung, A. H., Yang, V. K., & Chen, H. H. (2025) · Pharmaceuticals · doi:10.3390/ph18050671 · Cited by 3
Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial
Lyhne, J. D., Hansen, V. B., Vestergaard, L. D., Hosbond, S. E., Busk, M., Gnanaganesh, M., Maae, E., Havelund, B. M., Hansen, T. F., Timm, S., et al. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00344-3 · Cited by 3
From awareness to action: Revolutionizing cardio-oncology in China
Wang, A., & Liu, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.011 · Cited by 3
High-Intensity Interval Training During Cancer Prehabilitation May Improve Cardiorespiratory Fitness: A Meta-Analysis
Cuomo, S., Brustio, P. R., Mulasso, A., Beratto, L., Dieli-Conwright, C. M., & Rainoldi, A. (2025) · Healthcare · doi:10.3390/healthcare13233030 · Cited by 3
Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999–2023
Tian, Y., Guo, X., & Zhang, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05417-w · Cited by 3
Protective effects of Melissa officinalis ethanolic extract on doxorubicin-induced cardiotoxicity in a rat model
Terzic, J., Veljkovic, L., Jakovljevic, V. L., Novakovic, J. N., Sretenovic, J. Z., Muric, M. D., Kočović, A. G., & Milosavljevic, I. M. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0217 · Cited by 3
Heart failure related cardiotoxicity in breast cancer survivors: a scoping review
Vacharanukrauh, P., Miller, K. J., Alif, S. M., Grace, F., & Rahman, M. A. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00434-2 · Cited by 3
Cardioprotection for radiation-induced heart disease in breast cancer patients
Mędrek, S., Rolek, K., Homotnik, J., & Szmit, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1742769 · Cited by 3
Assessment of left ventricular diastolic dysfunction following anthracyclinebased chemotherapy in breast cancer patients
Sumin, A. N., Shcheglova, A. V., Slepynina, Y. S., Ivanova, A. V., & Polikutina, O. M. (2022) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2022-7.3.13 · Cited by 3
Advanced Echocardiographic Techniques in Cardio-Oncology: the Role for Early Detection of Cardiotoxicity
Gálvez, L. C., Redondo, E. A., Lorenzo, C. C., & López‐Fernández, T. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01728-y · Cited by 3
A probabilistic generative model to discover the treatments of coexisting diseases with missing data
Zaballa, O., Pérez, A., Gómez-Inhiesto, E., Acaiturri-Ayesta, T., & Lozano, J. A. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107870 · Cited by 3
Prognostic impact of coexisting cardiovascular disease in patients with cancer: A multicenter retrospective cohort study
Kuwabara, Y., Morishima, T., Kudo, H., Ma, C., Kato, M. S., Koyama, S., Nakata, K., Tabuchi, T., & Miyashiro, I. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25594 · Cited by 3
Prevention of anthracycline and trastuzumab‐induced decline in left ventricular ejection fraction with angiotensin‐converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials
Lee, S., Alsamarrai, A., Xiao, A., & Wang, T. K. M. (2024) · Internal Medicine Journal · doi:10.1111/imj.16437 · Cited by 3
Brazilian Guideline on Menopausal Cardiovascular Health – 2024
de Oliveira, G. M. M., de Almeida, M. C. C., Artucio, C., Espíndola, L. N., Rivera, M. A. M., Filho, A. L. D. S., Marques-Santos, C., Fernandes, C. E., Albuquerque, C. J. D. M., Freire, C. M. V., et al. (2024) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2024rbgo100 · Cited by 7
Unveiling the Complexities: Exploring Mechanisms of Anthracyclineinduced Cardiotoxicity
Tayal, R., Mannan, A., Singh, S., Dhiman, S., & Singh, T. G. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x322928241021100631 · Cited by 3
Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study
Kuroda, J., Oikawa, M., Tokuda, E., Tachibana, K., Sasaki, E., Ohtake, T., Takeishi, Y., & Saji, S. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-09067-0 · Cited by 3
Reduced Homogeneous Myocardial [18F]FDG Uptake in Routine PET/CT Studies as an Early Indicator of Chemotherapy-Induced Cardiotoxicity
Palomino-Fernández, D., Bueno, H., López-Guarch, C. J., Moreno, G., Seiffert, A. P., Aguilera, E. J. G., Gómez‐Grande, A., & González, P. S. (2024) · Applied Sciences · doi:10.3390/app142411653 · Cited by 3
Cancer Prehabilitation
Brown, C., Orada, R. B., & Henderson, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-72862-4_6 · Cited by 3
Significance of left ventricular strain in cardiac magnetic resonance for short-term prognosis in pediatric patients with acute lymphoblastic leukemia
Jin, W., Yang, J. Y., Liao, Y., Xie, L., Lei, X., Guo, Y., Liu, L., Wang, Y., Yang, Z., Lin, C., et al. (2025) · Pediatric Radiology · doi:10.1007/s00247-025-06168-8 · Cited by 3
The Cardiotoxicity Risk of Immune Checkpoint Inhibitors Compared with Chemotherapy: A Systematic Review and Meta-analysis of Observational Studies
Zheng, Y., Liu, Z., Chen, D., Zhang, J., Yuan, M., Zhang, Y., Liu, S., Zhang, G., & Yang, G. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-09979-1 · Cited by 4
UPLC-Q-TOF-MS based investigation into the bioactive compounds and molecular mechanisms of Qishen Huanwu capsule attenuates anthracycline-induced cardiotoxicity
Lv, J., Wang, L., Yang, J., Dong, J., Feng, N.-N., Liu, H., Zhao, N., Yin, G., & Wang, F. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156877 · Cited by 3
Challenges and opportunities for improving cardiovascular health in women with breast cancer: a review
Ali, S., & Mullen, K. A. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00362-1 · Cited by 3
Machine learning modeling of cancer treatment-related cardiac events in breast cancer: utilizing dosiomics and radiomics
Dincer, S., Akmansu, M., & Akyol, O. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1557382 · Cited by 3
Trastuzumab Cardiotoxicity: Mechanism and Management
Wakasa, M., Masaki, M., & Kajinami, K. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00235 · Cited by 3
Sacubitril/valsartan versus candesartan in women with heart failure receiving adjuvant therapy for breast cancer - is there any antiarrhythmic effect?
Канорский, С. Г., & Pavlovets, V. P. (2020) · Journal of Arrhythmology · doi:10.35336/va-2020-3-34-41 · Cited by 3
Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity
Murkamilov, I. T., Айтбаев, К. А., Fomin, V. V., Орозобаевна, К. И., Yusupov, F. A., & Абдилалимовна, М. Ж. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2583 · Cited by 3
Primera declaración Mexicana en materia de Insuficiencia Cardiaca
Gamba, M. A. A., Borrayo–Sánchez, G., Gutiérrez‐Fajardo, P., Aponte, A. T., Ruiz, V. E. R., Flores, D. C., Garza, E. H. H., Garaygordobil, D. A., Sánchez, C. A. G., Álvarez‐Álvarez, R. J., et al. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/98870 · Cited by 4
Bortezomib-Induced Reversible Cardiomyopathy: Recovered with Guideline-Directed Medical Therapy
Sundaravel, S., Marar, R. I., Abbasi, M. A., Baljević, M., & Stone, J. (2021) · Cureus · doi:10.7759/cureus.20295 · Cited by 3
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
Conte, B., Montemurro, F., Levaggi, A., Blondeaux, E., Molinelli, C., Cardinali, B., Poggio, F. B., Buzzatti, G., Bighin, C., Lambertini, M., et al. (2022) · Tumori Journal · doi:10.1177/03008916211067568 · Cited by 3
Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma ― A Single Institute Analysis ―
Wang, X., Nakano, K., Shiga, T., Ohmoto, A., Oyakawa, T., Ebihara, A., Sato, Y., Fukuda, N., Nishizawa, M., Urasaki, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-0808 · Cited by 3

Authors: Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C. M., Dent, S., & Jordan, K.
Affiliations: University of Milan (IT)
Washington University Medical Center (US)
University of South Florida (US)
Lahey Hospital and Medical Center (US)
Georgetown University (US)
University of Minnesota (US)
Mayo Clinic (US)
University of Kansas Medical Center (US)
Royal Brompton Hospital (GB)
Centre Hospitalier Universitaire de Liège (BE)
University of Chicago (US)
Vanderbilt University (US)
Stanford Medicine (US)
European Institute of Oncology (IT)
Hospital Universitario Ramón y Cajal (ES)
Washington University in St. Louis (US)
Tel Aviv University (IL)
Hospital of the University of Pennsylvania (US)
City Of Hope National Medical Center (US)
University of Pennsylvania (US)
Duke University (US)
Heidelberg University (DE)
ORCID: Curigliano, G.
Lenihan, D.
Fradley, M.
Ganatra, S.
Barac, A.
Blaes, A.
Porter, C.
Lyon, A.R.
Patel, A.
DeCara, J.
Mitchell, J.
Moslehi, J.
Witteles, R.
Orecchia, R.
Krone, R.
Iakobishvili, Z.
Carver, J.
Armenian, S.
Ky, B.
Cardinale, D.
Cipolla, C.M.
Dent, S.
Jordan, K.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2020-02
Volume: 31
Issue: 2
Pages: 171-190
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/j.annonc.2019.10.023
PMC: PMC8019325
OpenAlex: W2999536665
Cited by: 1,031
References: 221
Citations by year: 2026: 108 · 2025: 152 · 2024: 168 · 2023: 189 · 2022: 188 · 2021: 143 · 2020: 83
FWCI: 93.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ORBi (University of Liège) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: HF
Genentech
Amgen
Servier
Pfizer
Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: cardio-oncology, cardiotoxicity, cancer therapy, heart failure, cardiovascular screening, cardiovascular monitoring, novel cancer therapies, cardiovascular disease in cancer patients
MeSH terms: Antineoplastic Agents, Heart Diseases, Humans, Medical Oncology, Neoplasms, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks